Shots: The companies collaborated to provide GSK with additional capacity to manufacture and supply GSK’s innovative biopharmaceutical therapies. The eight-year contract is valued at more than $231M This capacity will be flexible depending on GSK’s future needs and will supplement GSK’s existing manufacturing network Samsung Biologics will commercially produce GSK’s Benlysta (belimumab) with technology transfer […]Read More
